Ethicon Buys Acclarent: Can This Exit Open Up ENT?

Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. Indeed, it has been more than a decade since the last major ENT deal, which made Medtronic the sole major strategic player in the ENT space. That dynamic has now changed with J&J/Ethicon's acquisition of Acclarent. Now the question is whether this deal will help open up the ENT space to more M&A activity?

Traditionally, the ENT space has been a bit of a technology backwater in terms of device innovation. The natural conservatism of ENT surgeons combined with a culture in which the various specialty societies reinforce this perspective through their reluctance to embrace new approaches and resistance to revising reimbursement and other regulatory issues have discouraged entrepreneurs and investors from spending much time or money in this space. This has resulted in a lack of start-up activity in this area and a concomitant lack of deal making. Indeed, it has been more than a decade since the last major ENT deal, which was Medtronic PLC's acquisition of Xomed Surgical (now Medtronic Xomed Inc.) for $736 million in 1999. [See Deal]

As a result of that deal, Medtronic became the sole major strategic player in the ENT space, which is another...

More from Business Strategy

More from In Vivo

Podcast: ADDF’s Karen Harris On Investing In Alzheimer’s Like A VC

 
• By 

A discussion with Karen Harris, CFO of the Alzheimer's Drug Discovery Foundation, about the foundation's investment strategy, biotech and investor sentiment at the recent BIO conference and what innovations give her hope for Alzheimer's patients.

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.

AI Agents Set To Reshape Biopharma’s Workforce And Operations

 
• By 

While biopharma companies experiment with genAI, agentic AI is rapidly shifting the work paradigm towards one of autonomous digital workers that can handle entire process flows.